newsfilter
← Latest News
Business Wire·

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced